Home » Millennium Says Heavy R&D Costs, Acquisition Fees Offset Strong Revenue Growth in Q3

Millennium Says Heavy R&D Costs, Acquisition Fees Offset Strong Revenue Growth in Q3

Oct 15, 2002

NEW YORK, Oct. 15 - Millennium Pharmaceuticals today reported that a jump in R&D spending and the cost of acquiring Cor Therapeutics in February offset a surge in total revenue during the third quarter.

 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The Scan

This Week in Science

In Science this week: International Wheat Genome Sequencing Consortium publishes the bread wheat cultivar Chinese Spring reference genome, and more.

New Framework Suggested

At his FDA Law Blog, Jeffrey Gibbs discusses FDA's technical assistance for the draft Diagnostic Accuracy and Innovation Act.

Penguins With Roving Eyes

The New York Times reports that genetic testing has uncovered unfaithful penguins at a Utah aquarium.

Funding Lost

Cancer researcher loses funding under new Wellcome Trust anti-bullying policies, the Guardian reports.

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2018 GenomeWeb LLC.  All Rights Reserved.